Open Access

Altered expression of striatin‑4 is associated with poor prognosis in bladder transitional cell carcinoma

  • Authors:
    • Yuhan Zhang
    • Xinquan Gu
    • Fuquan Jiang
    • Pinghui Sun
    • Xu Li
  • View Affiliations

  • Published online on: February 25, 2021     https://doi.org/10.3892/ol.2021.12592
  • Article Number: 331
  • Copyright : © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Striatin‑4 (STRN4 or Zinedin) is a scaffolding protein belonging to the mammalian STRN family of proteins and consists of multiple functional signaling domains. Due to its numerous signaling complexes, STRN4 has been reported to be involved in the tumorigenesis of various cancer types, including colon cancer, liver cancer and prostate cancer. However, few studies on STRN4 have been conducted in bladder cancer, and its prognostic role in bladder cancer remains unknown. The present study aimed to investigate the expression levels of STRN4 in bladder transitional cell carcinoma and evaluate the prognostic role of STRN4. STRN4 expression in clinical specimens was analyzed using immunohistochemistry and reverse transcription‑quantitative PCR. It was demonstrated that STRN4 expression was significantly associated with clinical parameters such as tumor size, muscle invasion depth and pathological tumor grade. Abnormal STRN4 expression was typically associated with worse overall survival time and outcome when compared with the low STRN4 expression group. Using multivariate analysis, it was reported that STRN4 was an independent prognostic biomarker for survival time in bladder transitional cell carcinoma. Although the specific biological mechanisms of STRN4 in bladder cancer still remain to be elucidated, STRN4 expression could be a prognostic indicator in bladder cancer.

Introduction

Bladder cancer has been categorized as the ninth most commonly diagnosed cancer worldwide in 2016 and ranked as the fourth in the USA in 2018 (1). Unlike other malignancies, the morbidity and mortality of bladder cancer remained stable from 1975 to 2014 despite oncology advances in novel medicine treatment or diagnosis over these years, even with small increases in morbidity and mortality rates during a specific time period (2). The 5-year survival rate of patients with bladder cancer was 73% between 1994 and 1998 and 76% between 2009 and 2013 worldwide (3). These data indicate that current treatment approaches targeting bladder cancer have not significantly improved when it comes to prognosis. Hence, novel therapeutic procedures are urgently needed.

Striatin-4 (STRN4), also known as Zinedin, is a scaffolding protein of the mammalian STRN family of proteins that do not exert any enzymatic functions but serve as regulatory cascade subunits for protein phosphatase 2A (PP2A) (4). The STRN family consists of three highly homologous proteins: STRN, S/G2 Nuclear autoantigen (SG2NA) and STRN4. These three proteins manifest in a conservative manner due to their presence both in fungi and higher eukaryotes (5). Numerous studies have reported that the STRN proteins are expressed in various organs such as the central nervous system (6), lung, kidney and testis (7). However, the exact expression pattern differs, which indicates that the STRN family of proteins possess abundant but differential functions at the organ level or cellular level (8). For example, STRN is found to be expressed both in the central and peripheral nervous system, but mainly in the striatum and motor neurons. In addition, STRN is involved in the control of motor neurons and dendrite growth. SG2NA is highly expressed in the cerebellum and cortex, but it is most highly expressed during the S and G2 phases, which indicates its extensive involvement in cell cycle control (4,9). Similar to its homologous proteins, STRN4 contains four conserved functional domains that allow STRN4 to interact with numerous signaling pathways, such as the estrogen receptor signaling (STRN4-ERα) and RhoA pathways (10). These complex structural domains define its extensive involvement in biological and pathological processes. Previous reports have demonstrated that STRN4 participates in cell cycle regulation, Golgi assembly, apoptosis, neuron development and tumorigenesis, especially concerning its role in vascular formation (8,11,12).

Abnormal STRN4 expression can promote cell cycle progression and assist cancer cells in gaining invasive properties by activating downstream transcription factors, including misshapen-like kinase 1, RhoA, TRAF2 and NCK-interacting protein kinase (belonging to germinal center kinases) and platelet-derived growth factor receptor-α (PDGFRA) (13). Reznickova et al (13) have revealed that STRN4 functions as a fusion protein during the activation process of PDGFRA and accelerates the development of chronic eosinophilic leukemia (11,13). In another study, STRN4 was reported to promote cell proliferation and inhibit apoptosis in the prostate under the regulation of leukemia/lymphoma-related factor (14). However, to the best of our knowledge, there are no studies investigating the expression pattern of STRN4 in bladder cancer and the association between and STRN4 expression and prognosis.

The present study investigated the prognostic role of STRN4 in bladder cancer and aimed to determine the association between STRN4 and recurrence.

Materials and methods

Fresh samples and tumor specimens of bladder cancer

Up to 28 fresh excised bladder transitional cancer tissues along with 28 normal bladder tissues (3–3.5 cm away from the tumor) were collected after surgical removal at the China-Japan Union Hospital of Jilin University (Changchun, China) between December 2015 and December 2017. None of these patients had received anticancer therapy (including chemotherapy and targeted medicine) before surgery. The samples were immediately stored in liquid nitrogen (−196°C) for further experiments. A total of 112 bladder transitional cancer specimens with different Tumor-Node-Metastasis (TNM) stages (15) were obtained from the Department of Tissue Bank, China-Japan Union Hospital of Jilin University. Informed consent was obtained from all patients and the study was approved by The Ethics Committee of China-Japan Union Hospital of Jilin University (Changchun, China).

RNA harvest and reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from excised bladder cancer and normal tissues using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA with SMART® MMLV Reverse Transcriptase (cat. no. 639524; Takara Bio, Inc.). The mixture was heated at 70°C for 3 min, cooled down and subsequently centrifuged at 17,344 × g for 1 min at 4°C, incubated at 50°C for 60 min, and a final extension at 70°C for 15 min. RT-qPCR was performed to detect STRN4 expression using the 2−∆∆Cq method (16) with the PowerUp™ SYBR™ Green Master Mix (cat. no. A25742; Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's standard protocol. Primers were designed using the GPP Web Portal (https://portals.broadinstitute.org/gpp/public) and screened using the Blast function from both Primer Premier 6 (version 6.00; Premier Biosoft) and National Center for Biotechnology Information. STRN4 primers were purchased from Shanghai GenePharma Co., Ltd. The primer sequences were as follows: STRN4 Forward, 5′-GATCTCACCGTCACCAACGA-3′ and reverse, 5′-GGAACGAATGCCGTCGTAGT-3′. GAPDH was chosen as an internal control. qPCR was performed on the QuantStudio™ 5 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Initial denaturation at 95°C for 30 sec followed by 40 cycles of three-step PCR amplification comprising denaturation for 5 sec at 95°C, annealing for 34 sec at 60°C, and extension for 10 sec at 72°C.

Immunohistochemistry (IHC)

A total of 112 previously acquired formalin-fixed, paraffin-embedded bladder transitional cancer specimens along with 28 fresh samples and 28 matched adjacent non-cancerous tissues (ANCT) were cut into 4-µm thick slices and analyzed as previously described (17). Two pathologists who were blinded to the experimental data were invited to score each specimen's immunostaining degree using a light microscopy (Olympus Corporation; magnification, ×40). The images were captured using CellSens (version 2.3; Olympus Corporation). The immunostaining intensities were set as follows: 0 (No stain=blank), 1 (weak stain=light yellow), 2 (moderate stain=light brown) and 3 (strong stain=brown). In addition, the positive immunostaining proportions were categorized into four tiers: 0 (<10%), 1 (11–25%), 2 (26–50%) and 3 (>51%) (18). The intensity and proportion values were multiplied as the composite index. The marginal index (threshold) was set at 3. Specimens with composite index scores ≤3 were considered to have a low expression of STRN4. The STRN4 primary antibody (cat. no. ab230858; Abcam) titer was set at 1:100. Mouse IgG1 κ Isotype Control P3.6.2.8.1 (cat. no. 14-4714-82; eBioscience; Thermo Fisher Scientific, Inc.) was diluted at 1:100. IHC was performed under standard procedures according to the Abcam manufacturer's protocol.

Statistical analysis

Data are presented as the mean ± SD (unless otherwise shown) with each experiment performed in triplicate. Statistical analysis between two groups was evaluated using two-tailed unpaired Student's t-tests and Fisher's exact tests using GraphPad Prism 7 (GraphPad Software, Inc.). The association between STRN4 expression and clinicopathological parameters of bladder transitional carcinoma was analyzed using the χ2 test. The survival data of up to 165 patients were collected from the epidemiology and statistics database (jointly built with First hospital of Jilin University) from the School of Public Health, Jilin University. Survival curves were established using the Kaplan-Meier method and compared using log-rank tests with SPSS 26.0 (IBM Corp.) and multivariate analysis was conducted using a Cox regression model. P<0.05 was considered to indicate a statistically significant difference.

Results

STRN4 is overexpressed in bladder transitional carcinoma

In order to determine STRN4 expression in bladder transitional cancer, IHC was performed on 28 pairs of fresh bladder tumor samples. As shown in Fig. 1A, the location and expression of STRN4 varied in different TNM stages. In relatively early TNM stages, STRN4 was mainly located at the cell membrane. Upon progression of TNM stage, STRN4 was located primarily in the cytoplasm and with increased expression. T2N0M0 indicates stage II in TNM stages. T3aN0M1 and T4N1M1 represents stage IV in bladder cancer.

Moreover, the present study analyzed STRN4 mRNA expression of patients with bladder carcinoma from the epidemiology and statistics database from the School of Public Health, Jilin University (19). STRN4 was significantly overexpressed in cancer samples (43 cases) compared with ANCT (23 cases) (P<0.001; Fig. 1B). Additionally, STRN4 mRNA expression in 28 paired samples was examined and presented as a heat map (Fig. 1C). RT-qPCR verified that STRN4 mRNA expression was significantly increased compared with the ANCT group by an average of 1.81-fold (maximum, 6.05-fold; P<0.001; data not shown). In summary, these results suggested that STRN4 is overexpressed in human bladder transitional cell carcinoma.

Aberrant STRN4 expression is associated with clinicopathological features

In order to investigate the association between STRN4 expression and specific clinical parameters, certain features such as age, sex, tumor size and muscle infiltration were chosen to measure the effects of STRN4 expression. As shown in Table I, STRN4 expression was significantly associated with tumor size (P=0.005564), muscle infiltration (P=0.000357), pathological tumor grade (P=0.001500) and microvascular invasion (P=0.034741). However, STRN4 expression was not statistically associated with age (P=0.542109), sex (P=0.240841) and lymph node involvement (P=0.232024). High STRN4 expression in patients with high grade bladder carcinoma was 84.2% (59/70) compared with 57.1% (24/42) in patients with low grade bladder carcinoma. STRN4 was detected in 77.5% (69/89) of cases with deep muscle infiltration (T2-T4) compared with superficial tumor invasion (Ta-T1), which was 39.1% (9/23). In patients with microvascular invasion, the detection rate of STRN4 was 81.5% (53/65) compared with 63.8% (30/47) in the low expression group. The immunostaining scores of 112 samples are listed in graphical form (Fig. 2). The number of specimens with different immunostaining scores are listed below: 3 (score 0), 4 (score 1), 7 (score 2), 15 (score 3), 38 (score 4), 30 (score 6), 15 (score 9). High STRN4 expression (score >3) was detected in 74.1% (83/112) of cases compared with cases with low expression (score ≤3), which was 25.9% (29/112).

Table I.

Correlation between STRN4 expression and clinicopathological parameters in patients with bladder transitional carcinoma.

Table I.

Correlation between STRN4 expression and clinicopathological parameters in patients with bladder transitional carcinoma.

STRN4 expression

Clinical pathological variableNumber of patientsLow, n (%)High, n (%)P-value
Total11229 (25.9)83 (74.1)
Age, years 0.542109
  <653512 (34.3)23 (65.7)
  ≥657722 (28.6)55 (71.4)
Sex 0.240841
  Male8136 (44.4)45 (55.6)
  Female3110 (32.3)21 (67.7)
Tumor size, cm 0.005564
  <38231 (37.8)51 (62.2)
  ≥3306 (20.0)24 (80.0)
Muscle infiltration 0.000357
  Ta-I2314 (60.9)9 (39.1)
  T2-T48920 (22.5)69 (77.5)
Lymph node involvement 0.232024
  No10046 (46.0)54 (54.0)
  Yes125 (41.7)7 (58.3)
Pathological tumor grade 0.001500
  Low4218 (42.9)24 (57.1)
  High7011 (15.8)59 (84.2)
Microvascular invasion 0.034741
  No4717 (36.2)30 (63.8)
  Yes6512 (18.5)53 (81.5)

[i] STRN4, striatin-4; T, tumor.

High STRN4 expression in bladder transitional cancer is associated with adverse survival outcomes

As shown in Fig. 3A, the mean survival time of patients with high STRN4 expression was 35.82±2.874 months (n=83), which was significantly lower compared with the low expression group (48.77±3.86 months; n=82; P=0.0077). Kaplan-Meier survival curves demonstrated that patients with high STRN4 expression ended up having a significantly shorter overall survival time compared with patients with lower STRN4 expression (P<0.001; Fig. 3B). Multivariate analysis was conducted to determine whether STRN4 expression could serve as a risk factor. STRN4 expression, along with other possible prognostic factors, were analyzed using Cox regression analysis. As shown in Table II, low pathological tumor grade could serve as a protective factor (coefficient=−0.951). The risk level of patients with low pathological tumor grades was 0.386 [hazard ratio (HR)=0.386] when compared with the high tumor grade group. The risk of patients with no relapse was 0.242 [hazard ratio (HR)=0.242] compared with patients with recurrence. STRN4 expression could serve as an independent factor for evaluating prognosis in patients with bladder transitional carcinoma (P=0.0018).

Table II.

Multivariate analysis of the association between clinical indexes and survival time of patients with bladder cancer.

Table II.

Multivariate analysis of the association between clinical indexes and survival time of patients with bladder cancer.

95.0% CI for HR

VariableCoefficientStandard errorχ2dfHRP-valueLowerUpper
Age, ≥65 vs. <65 years0.0220.0104.63310.03141.0221.0021.043
Sex, male vs. female−0.1930.2940.43210.51120.8240.4631.467
Muscle infiltration, T2-T4 vs. Ta-T11.1400.30414.09210.00023.1261.7245.668
Expression group, high vs. low0.8320.2679.69010.00182.2971.3613.879
Pathological tumor grade high vs. low−0.9510.4105.38610.02030.3860.1730.863
Recurrence status, yes vs. no−1.4200.6474.81410.02820.2420.0680.859

[i] df, degree of freedom; HR, hazard ratio; CI, confidence interval.

Discussion

Bladder transitional cancer is known for its frequent recurrence after transurethral resection. The probability of 5-year recurrence for patients (mainly from UK, France, Spain and Netherlands in 2016) with European Organization for Research and Treatment of Cancer grades 1–4 is ~46%. Higher grade is accompanied by higher recurrence possibilities (2022). Hence, identifying novel indicators of recurrence is particularly important for patients with bladder tumors.

Through proteomic analysis, researchers have noted that STRN4 is included in the polyprotein complex known as STRN-interacting phosphatase and kinase (STRIPAK) as one of its core components (8,12,23). STRIPAK consists of several crucial proteins such as PP2A, germinal center kinase III, cerebral cavernous malformation 3 and monopolar spindle one-binder family 3 (2426). Accumulating evidence has indicated that STRN4 participates in the development of various cancer types and cardiac dysfunction via STRIPAK and STRIPAK-like complexes (27,28). Other reports have stated that the dysregulation of STRN4 expression exhibits potential for diagnosis and prognostic prediction (2931). However, the prognostic role of STRN4 in bladder cancer is unclear and needs to be further determined.

The present study first examined STRN4 expression in postoperative samples. The results demonstrated that STRN4 was distinctly overexpressed in bladder transitional cancer samples when compared with ANCT. Meanwhile, STRN4 mRNA expression was analyzed using qPCR and compared with database results. The present study concluded that STRN4 mRNA expression was significantly higher compared with the ANCT group and the overexpression pattern was consistent with database results. These results indicated that STRN4 expression was upregulated in bladder transitional cancer.

To further elucidate the clinical relevance of STRN4, the association between STRN4 and several clinicopathological indexes were analyzed. STRN4 was significantly associated with tumor size, muscle infiltration, pathological grade and microvascular invasion. Muscle infiltration, pathological grade and microvascular invasion were listed as some of the most crucial factors for evaluating patient survival time and prognosis. The association between these variables and patient outcome is not strictly confined to bladder cancer, but also in other malignancies (3234). Hence, STRN4 may serve a role as an independent prognostic factor. Furthermore, since the main metastasis approach for bladder transitional carcinoma is still muscle intrusion, these results suggested that STRN4 is important in tumor metastasis and recurrence, and may serve as an effective indicator for progression.

To determine the prognostic value of STRN4, survival analysis was performed to determine the effects of STRN4 on patient OS time. It was demonstrated that patients with high STRN4 expression had a lower OS time compared with the low expression group. Multivariate analysis indicated that STRN4 was an independent positive prognostic factor for OS. Taken together, the present results demonstrated that STRN4 may be a potential indicator for the prognosis of patients with bladder cancer and could be a new therapeutic target. To conclude, the present study indicated that STRN4 is an independent prognostic factor and potential therapeutic target for patients with bladder transitional carcinoma.

The present study is not without limitations. First, the analysis between STRN4 expression and the clinical parameters only consisted of 112 samples. Larger sample sizes are required to validate the results presented here. In addition, STRN4 mRNA expression analysis was performed using 43 cancer samples and only 23 ANCT samples. For prospective studies, equivalent samples are required to exclude interference from confounding and mismatching factors. Further studies are also required to determine the molecular mechanisms underlying the abnormal expression of STRN4 in the tumorigenesis of bladder transitional carcinoma.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Doctor Training Fund Subdivision of China-Japan Union Hospital of Jilin University (grant no. 4700404B003C).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

XG, XL planned and designed the experiments and collected and analyzed the data. YZ validated the results, performed the experiments and drafted the manuscript. FJ, PS analyzed and interpreted the data. XL and YZ confirmed the authenticity of all raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was supervised and approved by the Ethics Committee of China-Japan Union Hospital of Jilin University (Changchun, China; approval no. 2015-wjw014), and performed in compliance with the Declaration of Helsinki. Written informed consent was provided by all patients prior to the study start.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Malmström PU: Why has the survival of patients with bladder cancer not improved? BJU Int. 101:267–269. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Benoist M, Gaillard S and Castets F: The striatin family: A new signaling platform in dendritic spines. J Physiol Paris. 99:146–153. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Tanabe O, Hirata D, Usui H, Nishito Y, Miyakawa T, Igarashi K and Takeda M: Fission yeast homologues of the B' subunit of protein phosphatase 2A: Multiple roles in mitotic cell division and functional interaction with calcineurin. Genes Cells. 6:455–473. 2001. View Article : Google Scholar : PubMed/NCBI

6 

Castets F, Rakitina T, Gaillard S, Moqrich A, Mattei MG and Monneron A: Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J Biol Chem. 275:19970–19977. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Soni S, Jain BP, Gupta R, Dharavath S, Kar K, Komath SS and Goswami SK: Biophysical characterization of SG2NA variants and their interaction with DJ-1 and Calmodulin in vitro. Cell Biochem Biophys. 76:451–461. 2018. View Article : Google Scholar : PubMed/NCBI

8 

Hwang J and Pallas DC: STRIPAK complexes: Structure, biological function, and involvement in human diseases. Int J Biochem Cell Biol. 47:118–148. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Castets F, Bartoli M, Barnier JV, Baillat G, Salin P, Moqrich A, Bourgeois JP, Denizot F, Rougon G, Calothy G and Monneron A: A novel calmodulin-binding protein, belonging to the WD-repeat family, is localized in dendrites of a subset of CNS neurons. J Cell Biol. 134:1051–1062. 1996. View Article : Google Scholar : PubMed/NCBI

10 

Pojoga LH, Coutinho P, Rivera A, Yao TM, Maldonado ER, Youte R, Adler GK, Williams J, Turchin A, Williams GH and Romero JR: Activation of the mineralocorticoid receptor increases striatin levels. Am J Hypertens. 25:243–249. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Lin L, Lo LH, Lyu Q and Lai KO: Determination of dendritic spine morphology by the striatin scaffold protein STRN4 through interaction with the phosphatase PP2A. J Biol Chem. 292:9451–9464. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Wong M, Hyodo T, Asano E, Funasaka K, Miyahara R, Hirooka Y, Goto H, Hamaguchi M and Senga T: Silencing of STRN4 suppresses the malignant characteristics of cancer cells. Cancer Sci. 105:1526–1532. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Reznickova E, Gucky T, Kovacova V, Ajani H, Jorda R and Krystof V: Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity. Eur J Med Chem. 182:1116632019. View Article : Google Scholar : PubMed/NCBI

14 

Jiang F, Zheng Q, Chang L, Li X, Wang X and Gu X: Pro-oncogene pokemon promotes prostate cancer progression by inducing STRN4 expression. J Cancer. 10:1833–1845. 2019. View Article : Google Scholar : PubMed/NCBI

15 

Cornejo KM, Rice-Stitt T and Wu CL: Updates in staging and reporting of genitourinary malignancies. Arch Pathol Lab Med. 144:305–319. 2020. View Article : Google Scholar : PubMed/NCBI

16 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Wang X, Jiang F, Song H, Li X, Xian J and Gu X: MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. Biochem Biophys Res Commun. 470:620–626. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Li X, Jiang F, Wang X and Gu X: SPAG9 regulates HEF1 expression and drives EMT in bladder transitional cell carcinoma via rac1 signaling pathway. Am J Cancer Res. 8:2467–2480. 2018.PubMed/NCBI

19 

Du B, Liu S, Cui C, Wang S and Cui W: Association between glucose transporter 1 rs841853 polymorphism and type 2 diabetes mellitus risk may be population specific (1rs8418532). J Diabetes. 5:291–299. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Gakis G, Witjes JA, Comperat E, Cowan NC, De Santis M, Lebret T, Ribal MJ and Sherif AM; European Association of Urology, : EAU guidelines on primary urethral carcinoma. Eur Urol. 64:823–830. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Goudreault M, D'Ambrosio LM, Kean MJ, Mullin MJ, Larsen BG, Sanchez A, Chaudhry S, Chen GI, Sicheri F, Nesvizhskii AI, et al: A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics. 8:157–171. 2009. View Article : Google Scholar : PubMed/NCBI

24 

Gordon J, Hwang J, Carrier KJ, Jones CA, Kern QL, Moreno CS, Karas RH and Pallas DC: Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3. BMC Biochemistry. 12:542011. View Article : Google Scholar : PubMed/NCBI

25 

Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, Coubes P, Echenne B, Ibrahim R, Irthum B, et al: Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet. 76:42–51. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Baillat G, Moqrich A, Castets F, Baude A, Bailly Y, Benmerah A and Monneron A: Molecular cloning and characterization of Phocein, a protein found from the golgi complex to dendritic spines. Mol Biol Cell. 12:663–673. 2001. View Article : Google Scholar : PubMed/NCBI

27 

Zheng Y, Liu B, Wang L, Lei H, Pulgar Prieto KD and Pan D: Homeostatic control of Hpo/MST kinase activity through autophosphorylation-dependent recruitment of the STRIPAK PP2A phosphatase complex. Cell Rep. 21:3612–3623. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Wagh V, Doss MX, Sabour D, Niemann R, Meganathan K, Jagtap S, Gaspar JA, Ardestani MA, Papadopoulos S, Gajewski M, et al: Fam40b is required for lineage commitment of murine embryonic stem cells. Cell Death Dis. 5:e13202014. View Article : Google Scholar : PubMed/NCBI

29 

Shi Z, Jiao S and Zhou Z: STRIPAK complexes in cell signaling and cancer. Oncogene. 35:4549–4557. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Madsen CD, Hooper S, Tozluoglu M, Bruckbauer A, Fletcher G, Erler JT, Bates PA, Thompson B and Sahai E: STRIPAK components determine mode of cancer cell migration and metastasis. Nat Cell Biol. 17:68–80. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Chen M, Zhang H, Shi Z, Li Y, Zhang X, Gao Z, Zhou L, Ma J, Xu Q, Guan J, et al: The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer. J Biol Chem. 293:14455–14469. 2018. View Article : Google Scholar : PubMed/NCBI

32 

Wahlin S, Nodin B, Leandersson K, Boman K and Jirstrom K: Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: A comparative study of transurethral resection and cystectomy specimens. Oncoimmunology. 8:e16441082019. View Article : Google Scholar : PubMed/NCBI

33 

Lionello M, Bertolin A, Nardello E, Giacomelli L, Canal F, Rizzotto G, Marioni G and Lucioni M: Could the infiltration of the thyroarytenoid muscle define the pT2 glottic carcinoma? Head Neck. 41:3639–3646. 2019. View Article : Google Scholar : PubMed/NCBI

34 

Botling J, Lamarca A, Bajic D, Norlen O, Lonngren V, Kjaer J, Eriksson B, Welin S, Hellman P, Rindi G, et al: High-grade progression confers poor survival in pancreatic neuroendocrine tumors. Neuroendocrinology. 110:891–898. 2020. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April-2021
Volume 21 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Gu X, Jiang F, Sun P and Li X: Altered expression of striatin‑4 is associated with poor prognosis in bladder transitional cell carcinoma. Oncol Lett 21: 331, 2021
APA
Zhang, Y., Gu, X., Jiang, F., Sun, P., & Li, X. (2021). Altered expression of striatin‑4 is associated with poor prognosis in bladder transitional cell carcinoma. Oncology Letters, 21, 331. https://doi.org/10.3892/ol.2021.12592
MLA
Zhang, Y., Gu, X., Jiang, F., Sun, P., Li, X."Altered expression of striatin‑4 is associated with poor prognosis in bladder transitional cell carcinoma". Oncology Letters 21.4 (2021): 331.
Chicago
Zhang, Y., Gu, X., Jiang, F., Sun, P., Li, X."Altered expression of striatin‑4 is associated with poor prognosis in bladder transitional cell carcinoma". Oncology Letters 21, no. 4 (2021): 331. https://doi.org/10.3892/ol.2021.12592